Draft Therapeutic Products Bill

Slides:



Advertisements
Similar presentations
Armand Racine Consultant Chemicals Branch
Advertisements

Post Research Benefits Mandika Wijeyaratne MS, MD, FRCS Dept. of Surgery, Colombo.
Medsafe – GMP update / release for supply / communicating quality issues Derek Fitzgerald Manager, Compliance Management 11 July 2013 RACI Pharmaceutical.
Working Safer The building of a new regulatory regime September 2014 Bronwyn Turley and Susan Adams MBIE Policy.
Developing a Records & Information Retention & Disposition Program:
FEDERAL REGULATIONS OF MEDICATIONS Food, Drug and Cosmetic Act Protect consumers from adulterated and misbranded foods, drugs, cosmetics, or devices.
ARTSA Improving Heavy Vehicle Safety Summit Chain of Responsibility and its potential to improve safety Marcus Burke National Transport Commission 16 April.
1 Alvimopan RiskMAP Joyce Weaver, Pharm.D., BCPS Office of Surveillance and Epidemiology.
Supplies by pharmacists to entities other than patients.
New Zealand Medicines and Medical Devices Safety Authority A business unit of the Ministry of Health.
When do I need an IND ? FDA Guidance for Industry – Investigation New Drug Applications (INDs) - Determining Whether Human Research Studies Can Be Conducted.
Nuclearsafety.gc.ca Joint Congress on Medical Imaging and Radiation Sciences May 28, 2015 e-Doc CNSC Administrative Monetary Penalties Overview.
The National Registration and Accreditation Scheme and what it Means for the Health Workforce Martin Fletcher, Chief Executive Officer
Event Management & ITIL V3
Main Requirements on Different Stages of the Licensing Process for New Nuclear Facilities Module 4.1 Steps in the Licensing Process Geoff Vaughan University.
ACCESS TO MEDICINES - POLICY AND ISSUES
Preventive Controls for Human Food S upplemental Proposal 1
Special Railways Phase III Proposed approach to regulatory changes Jakarta 16 May 2011.
1 Proposed amendments to the National Environmental Management Act, 1998 (NEMA) October 2007 Presentation by Joanne Yawitch DDG EQP.
Investigational Devices and Humanitarian Use Devices June 2007.
INTRODUCTION TO DATA PROTECTION An overview of the Irish Data Protection legislation.
Medical Schemes Amendment Bill, 2002 Department of Health Briefing to Portfolio Committee on Health 3 September 2002.
Portfolio Committee for Health Medicines and Related Substances Amendment Bill (06/08/08) IMSA represents Research Based Pharmaceutical Companies.
October 28, F OOD AND DRUG ADMINISTRATION AMENDMENTS ACT OF 2007 (FDAAA) and Risk Evaluation and Mitigation Strategies (REMS) Presented to the Ninth.
The Changing Face of EU Legislation Is the EU moving towards the FDA model of pharmaceutical legislation? By Robert Smith Director.
Introduction to the Australian Privacy Principles & the OAIC’s regulatory approach Privacy Awareness Week 2016.
1 CHALLENGES IN REGULATING QUALITY AND RATIONAL USE OF ANTIBIOTICS ALLIANCE FOR THE PRUDENT USE OF ANTIBIOTICS: INAGURAL MEETING COURTYARD.
Date Insert on Master Slide Slide 1 Regulatory Framework within which patients can have safe and more convenient access to medicines Royal College of Physicians.
Medical Necessity Criteria An Overview of Key Components Presented by BHM Healthcare Solutions.
Addressing the Federal Legalization of Cannabis Briefing to Standing Committee on Priorities and Planning June 7, 2017.
POST APPROVAL CHANGE MANAGEMENT PROTOCOLS IN THE EUROPEAN UNION
Regulation of Medical Devices: Importance of a Globally Harmonized Approach Nicole Taylor Smith, JD September 2017.
OUS Data: What does the CE Mark Really Mean?
Health and Safety Policy
Addressing the Federal Legalization of Cannabis Briefing to Standing Committee on Priorities and Planning June 7, 2017.
Fair Go Rates System Dr Ron Ben-David Chairperson
Reforms to Support Safe and Timely Access to Medicines
Risk Communication in Medicines
FDA’s IDE Decisions and Communications
The New Legislative Framework Miniseminar New Legal Framework Reykjavík, 10 December 2008 Doris Gradenegger Unit C1: Regulatory Approach for the Free.
UNITED ADVISORY PARTNERS.
Supply Of Medical Goods) Bill
Pharmacovigilance in clinical trials
NATIONAL ENVIRONMENTAL MANAGEMENT:1st AMENDMENT BILL
Analysis of the Proposed Sunshine Rule: Legal Considerations
Establishing the Infrastructure for Radiation Safety Preparatory Actions and Initial Regulatory Activities.
Setting Actuarial Standards
Pre-Close Rules of Engagement
Proposal for a Regulation on medical devices and Proposal for a Regulation on in vitro diagnostic medical devices Key Provisions and GIRP Assessment.
GMP Inspection Process
Background (history, process to date) Status of CANs
Canadian Navigable Waters Act
Investor protection and MIFID
Legally Enforceable Data Collection
Fair Go Rates System Dr Ron Ben-David Chairperson
Linda M. Chatwin, Esq. RAC Business Manager, UL LLC
Importance of Law and Policies in the Environmental Management System
Legal Requirement on OHSC Complaints Management Presenter: Mr M Tlholoe Director Complaints Centre & Assessment Prepared for OHSC Consultative Workshops.
Therapeutic Products Bill
Medicines and Related Substances Amendment Bill RETAILERS’ ASSOCIATION Health Portfolio Committee, 6 August 2008.
Introduction of the new Canada Consumer Product Safety Act
Therapeutic Products Bill
Therapeutic Products Bill-consultation phase
Therapeutic Products Bill-consultation phase
Therapeutic Products Bill-consultation phase
Therapeutic Products Bill-consultation phase
Stakeholder Engagement: Webinar Part I: The Regulatory Development Process for the Government of Canada Part II: Making Technical Regulations Under.
Therapeutic Products Bill
Draft Therapeutic Products Bill
Compounded Drugs and Lack of Premarket FDA-Approval
Presentation transcript:

Draft Therapeutic Products Bill CONSUMER FORUM 21 March 2019

Today’s team Sheila Swan – Chief Advisor, Regulatory Policy, MoH Hannah Adams – Senior Analyst, Regulatory Policy, MoH Susan Martindale – Principal Policy Analyst, MoH Pamela Randell – Project coordinator, MoH

Agenda Item Welcome 1 Overview of the intended therapeutic products scheme: Regulatory instruments, product coverage, key controls, types of authorisations 2 Unapproved products / personal imports 3 Pharmacy licencing Tea and coffee 4 Access to pharmacy medicines 5 Advertising and information 6 Medical devices 7 Adverse event monitoring 8 Next steps te Item Indicative timing Welcome - 2.00 pm Overview of the intended therapeutic products scheme: Regulatory instruments, product coverage, key controls, types of authorisations - 2.10 pm Unapproved products / personal imports - 2.20 pm Pharmacy licencing- 2.40 pm Tea and coffee- 3.00 pm Access to pharmacy medicines- 3.15 pm Advertising and information- 3.25 pm Medical devices- 3.40 pm Adverse event monitoring- 4.05 pm Next steps- 4.10 pm Any other questions – 4.20 Close 4.30 pm

Overview of the intended therapeutic products regulatory scheme

Purpose & Design Purpose: The purpose of this Act is to protect personal and community health by- (a) ensuring acceptable safety, quality, and efficacy or performance of therapeutic products across their lifecycle; and (b) regulating the manufacture, import, promotion, supply, and administration or use of therapeutic products. Design Principles-based framework with three subordinate tiers.

Guiding principles The Regulator and any other person exercising a power under this Act must be guided by the purpose of this Act and the following principles: (a) the likely benefits of therapeutic products should outweigh the likely risks associated with them: (b) regulation of therapeutic products should- (i) be proportionate to the risks posed by the products; and (ii) support the timely availability of therapeutic products: (c) the administration of this Act should be carried on in an open and transparent manner: (d) there should be co-operation with overseas regulators, compliance with international obligations, and, if appropriate, alignment with international standards and practice.

There will be less detail in legislation and more in the regulations and regulator-made instruments Content Process Therapeutic Products Act Primary legislation sets out: the purpose of the Act provides a set of principles and criteria to set the parameters of the regulatory regime sets boundaries for the scope and development of subordinate legislative instruments contains the primary elements of the regulatory regime provides enforcement powers sets out accountability arrangements Made by Parliament  Regulations Regulations will contain further detail on: matters not appropriately dealt with in regulator-made instruments (such as fee setting) matters to do with accountability key elements of the regulatory regime that will remain relatively stable and which are significant to the design of the regulatory requirements Schedule 3 lists the matters that can be specified in regulations Made by the Governor-General, by Order and Council Regulations will be subject to review by the Regulations Review Committee Rules Contain the detail of the regulatory requirements Schedule 3 lists the matters that can be specified in rules Made by the regulator Subject to review by the Regulations Review Committee Notices Covers operational aspects of the scheme Schedule 3 lists the matters that can be specified in notices The regulator must not issue a notice unless satisfied that doing so if necessary or desirable to promote the purposes of the Act; and it is no broader than is reasonable necessary to address matter that gave rise to it

A wider range of products would be covered The new system would regulate: Medicines This includes cell and tissue products and radiopharmaceuticals Medicines will continue to be classified: category 1 (prescription), category 2 (pharmacist), category 3 (pharmacy), category 4 (general sale) Active Medicinal Ingredients Defined separately from medicines, so a smaller set of controls can be applied to them Medical devices Type-4 products This is a catch all category for future therapeutic products that we don’t know about yet It will ensure the Regulator has the ability to apply regulatory requirements, as appropriate, when these products start coming to market. The Government will be considering regulation of natural health products as a separate process.

The scheme would consist of two broad components Product approval requirements Generally a TP can’t be imported or supplied unless it is approved. Exceptions are: the Regulator can declare some classes of product to be approval-exempt the import &/or supply of an unapproved product for a specific patient via a ‘special clinical needs supply authority’ a licence or permit or regulation can authorise the import &/or supply of an unapproved product (eg for a clinical trial) There will be different approval pathways possible Controlled activity restrictions The Bill regulates who is allowed to carry out certain activities involving therapeutic products (called controlled activities) and how those activities are carried out In addition, the Bill also: enables obligations to be imposed on people who in the course of business: import, supply, administer, use, or have possession of, any TPs imposes restrictions on advertising prohibits things such as tampering with, or misrepresenting, a TP.

The bill would enable flexibility in how controlled activities are authorised The draft Bill does not specify which type of authorisation should be used for particular controlled activities, but the general approach would be to use a: Bill or Regulations – when authorising a class of persons or all persons in a specific circumstance (eg. activities conducted by health practitioners) Licence – when authorising a particular person / or company on an on-going basis (eg. manufacturing, wholesale supply, pharmacy business) Permits – when authorising short-term or exceptional circumstance.

Proposed changes to either improve access or safety

Unapproved medicines The supply of an unapproved therapeutic product would require a ‘special clinical needs supply authority’ to ensure there is an active & recorded consideration of why an approved medicine is not appropriate The draft Bill requires a SCNSA for ‘off-label’ use of a medicine – We are considering this further, as it may cause practical issues As currently, the intention, is that only Medical Practitioners could issue a SCNSA for medicines that have not been approved in New Zealand However, once a SCNSA had been issued for a particular patient for a particular medicine, a health practitioner prescriber (who may not be a Medical Practitioner) then could prescribe that patient’s ongoing supply.

Personal import of medicines Objective - To balance personal freedom against protecting consumers from substandard, adulterated, or counterfeit medicines The Bill contains an authorisation that would continue to allow: people to bring all categories of medicines with them into the country import via post/courier of non-prescription medicines from other countries There is no authorisation for people to personally import prescription medicines via post/courier. They would need to seek a special clinical needs supply authority and obtain the medicine from their prescriber or a pharmacy once it had been imported for them. We envisage the importer would usually be a wholesaler It would be possible to use permits to authorise the personal import of prescription medicines via post/courier in some situations, if appropriate.

Pharmacy licensing – Enabling new supply and distribution models The definition of a ‘pharmacy business’ is based on the pharmacy activities, rather than the pharmacy premise Pharmacy licences would be able to authorise pharmacy activities involving medicines to occur in different locations. For example: Mobile pharmacies A pharmacist could be licensed to visit rest homes and supply particular medicines A pharmacist could be licensed to provide marae-based services involving medicines The licence and its requirements would only be focused on what activities are occurring as part of a pharmacy business We are also seeking feedback on whether the requirement for a pharmacist to be present should enable situations where this is provided virtually (eg, via skype).

Pharmacy - Options for ensuring a pharmacist is in control of a pharmacy business Option 1: Strengthened accountability though pharmacist ownership and effective control Retain and strengthen the requirement that a pharmacist(s) has majority ownership and effective control of the pharmacy business Potential benefits: Reduced risk of negative impact of increased commercial interest in, and influence over, pharmacies Option 2: Open ownership with licence requirements targeted at pharmacist control of quality systems and practices within the pharmacy The responsible persons for a pharmacy licence would need to be a pharmacist. They would need to be responsible for: The quality management systems that impact pharmacy and pharmacist practice and the safe provision of therapeutic products The day-to-day implementation of those systems Potential benefits: Regulator efforts focused on pharmacy systems and practice, potential for greater investment in pharmacies.

Increasing access to pharmacy medicines Currently pharmacy medicines can only be provided from licensed pharmacy or retail-only (in remote areas lacking a pharmacy) business The Bill proposes to allow health practitioners, and their staff, to supply their patients with pharmacy medicines They would only be able to supply medicines within their scope of practice (eg a podiatrist could supply pharmacy medicines for foot or lower limb conditions).

Advertising It would continue to be an offence to advertise an unapproved product or include any false or misleading information in an advertisement for a therapeutic product There would be a wider range of enforcement tools available for non-compliance, including advertising remediation orders We are seeking feedback on whether direct-to-consumer advertising of prescription medicines should continue to be permitted.

Packaging, labelling and consumer medicine information The Bill enables packaging, labelling and consumer medicine information requirements to be set What these requirements should be would be set in regulations and rules We will consult when we are developing these regulations and rules.

Increased regulation of medical devices Currently there are no pre-market controls on medical devices and limited piecemeal post-market regulation The new scheme, would implement the international regulatory model, with a full suit of pre- and post-market controls for medical devices These controls would require: A licence for clinical trials of medical devices Product development data as part of product approval A licence for NZ manufacturers Overseas manufacturers to be audited and checked via the product approval process A pre-market product approval (with some exceptions) A register of all approved devices A licence for NZ wholesalers (unless exempt) Mandatory adverse event reporting by product sponsors Full suite of enforcement responses Where there are concerns, devices could be declared use- or supply-restricted.

Medical devices that are not therapeutic products The draft Bill only applies to therapeutic products A number of products have similar features and risks to medical devices, but are not intended for a therapeutic purpose Examples include: plano contact lenses, some facial or other dermal fillers, equipment used for cosmetic purposes that emits high-intensity electromagnetic radiation Are there products that are not for a therapeutic product that you consider should be regulated as part of this scheme?

Adverse event monitoring Companies importing and manufacturing medicines are required to report any untoward effects occurring in New Zealand or overseas that they are aware of, but are not required to have systems for monitoring their own products in the market Under the new scheme, it would be mandatory for product sponsors of both medicines and medical devices to have post market monitoring systems in place and to report any adverse events to the therapeutic products regulator The Bill also places a legal obligation on the regulator to have a system in place to monitor the safety of therapeutic products.

What next Sector forums in March Submissions due by 18 April Analysis of submissions & report back to Cabinet Draft Bill amended, as required Draft Bill introduced to Parliament Select Committee process (which usually includes a public submission process) Development of regulations, rules and notices – will involve consultation on detail of the scheme.